Drug intelligence / Profile preview

doxorubicin + paclitaxel + palonosetron

Development stage: Unknown
Lead developer: Helsinn
Modality: Small Molecules
Administration: Intravenous

Overview

This is a combination therapy consisting of two chemotherapeutic agents (doxorubicin and paclitaxel) with an antiemetic medication (palonosetron). Doxorubicin is an anthracycline chemotherapy drug, while paclitaxel is a taxane-based chemotherapeutic agent. Palonosetron is a 5-HT3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). Palonosetron has a higher binding affinity to 5-HT3 receptors and a significantly longer half-life (approximately 40 hours) compared to other drugs in its class, making it effective for both acute and delayed CINV.

Targets

TOP2A (DNA topoisomerase II)HTR3A (5-hydroxytryptamine receptor 3A)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on doxorubicin + paclitaxel + palonosetron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxorubicin + paclitaxel + palonosetron.

Explore the full profile